2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1084

Age Distribution of Women With Idiopathic and Traumatic Fibromyalgia
Abstract Number: 56

Age-Related Loss Of The Transforming Growth Factor Beta Receptor ALK5 Precedes Osteoarthritis Development In Cartilage
Abstract Number: 1531

Agreement Between Disease Activity States and Improvement Scores As Defined by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score Cut-Off Values
Abstract Number: 1311

Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort
Abstract Number: 46

Alarmins S100A8/A9 Regulate Osteophyte Formation In Experimental Osteoarthritis With High Synovial Activation
Abstract Number: 1431

Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Abstract Number: 1897

Algorithms Using Genome-Wide SNP Analysis For Prediction Of Progression Of Joint Space Narrowing Or Erosion In Rheumatoid Arthritis Patients Using Data From Multiple Medical Cohorts
Abstract Number: 265

All-Cause Mortality and Incident Cardiovascular Disease In Knee Osteoarthritis: The Framingham Study
Abstract Number: 1770

All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System
Abstract Number: 2229

Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate
Abstract Number: 1198

Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years
Abstract Number: 1189

Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Abstract Number: 475

Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Abstract Number: 1646

Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab
Abstract Number: 2193

Altered Apoptosis Profile and Associated Soluble Factors In Patients With Juvenile-Onset Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].